Headlands Technologies LLC Makes New $1.41 Million Investment in Merck & Co., Inc. $MRK

Headlands Technologies LLC bought a new position in Merck & Co., Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,997 shares of the company’s stock, valued at approximately $1,413,000.

Several other institutional investors also recently modified their holdings of MRK. Susquehanna Fundamental Investments LLC bought a new stake in Merck & Co., Inc. during the second quarter worth $11,470,000. Benjamin Edwards Inc. grew its stake in Merck & Co., Inc. by 36.3% in the 2nd quarter. Benjamin Edwards Inc. now owns 224,529 shares of the company’s stock valued at $28,854,000 after purchasing an additional 59,854 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Merck & Co., Inc. by 7.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 2,480,590 shares of the company’s stock valued at $318,756,000 after purchasing an additional 175,016 shares during the last quarter. Meiji Yasuda Life Insurance Co increased its position in shares of Merck & Co., Inc. by 4.1% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 14,833 shares of the company’s stock valued at $1,906,000 after purchasing an additional 590 shares during the last quarter. Finally, Thornburg Investment Management Inc. raised its stake in shares of Merck & Co., Inc. by 1.6% during the 2nd quarter. Thornburg Investment Management Inc. now owns 3,787,976 shares of the company’s stock worth $486,755,000 after purchasing an additional 59,303 shares during the period. 76.07% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares in the company, valued at approximately $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRK. Bank of America increased their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wolfe Research increased their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Guggenheim raised their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group lifted their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Finally, Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday, August 12th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.60.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $148.00 on Tuesday. The firm has a market capitalization of $365.14 billion, a PE ratio of 118.40, a P/E/G ratio of 6.22 and a beta of 0.19. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a 50-day moving average price of $132.43 and a two-hundred day moving average price of $122.67. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.